NEW YORK, Jan 16 – Curagen’s $124 million toxicogenomic and pharmacogenomic deal with Bayer and its $1.34 billion agreement to collaborate on drug targets for obesity and diabetes provide Curagen with the R&D budget necessary to enhance its portfolio of genomics tools and mine the genome for blockbuster drugs, analysts and company executives said Tuesday.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.